APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.

Other Secondary Efficacy Endpoints Since the secondary statistical gating assessment for the key secondary endpoint of RSB did not reach statistical significance, no formal noninferiority analyses were conducted between oliceridine and morphine responder rates.

also in 111,027 other papers